Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
In the last few decades, chimeric antigen receptor (CAR) T-cell therapy has led to a paradigm shift in the treatment of hematological malignancies, including various subtypes of B-cell non-Hodgkin’s lymphoma, B-cell acute lymphoblastic leukemia, and multiple myeloma. However, most patients experienc...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI AG
2025-09-01
|
| Colección: | Methods and Protocols |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/2409-9279/8/5/108 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|